{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:45:53Z","timestamp":1787946353581,"version":"build-2784847793"},"reference-count":98,"publisher":"The Royal Society","issue":"1957","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA201049"],"award-info":[{"award-number":["CA201049"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA242461"],"award-info":[{"award-number":["CA242461"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) are a frequent cause of non-small cell lung cancer (NSCLC). Osimertinib, a third-generation tyrosine kinase inhibitor (TKI) that is selective for mutant EGFR, is standard of care for patients with the classical exon 19 deletion variants and the L858R point mutation. Although osimertinib and a recently developed therapy that combines TKI lazertinib with the antibody amivantamab improve outcomes for these patients, resistance limits the durability of response to these agents. Additionally, patients with the L858R mutation do not respond as well as those with exon 19 deletions, highlighting the need for more effective therapies for these patients and for those with brain metastases, a common complication of these cancers. In this review, we survey the development of next-generation EGFR inhibitors with a particular focus on allosteric inhibitors developed for L858R-mutant NSCLC. EAI-432 and other allosteric EGFR inhibitors can co-bind with osimertinib, offering the possibility of double-drugging the mutant receptor to achieve deeper and more durable responses for EGFR L858R+ patients.<\/jats:p>\n                  <jats:p>This article is part of the discussion meeting issue \u2018Epidermal growth factor receptor after 40 years\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2024.0505","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:09:31Z","timestamp":1787814571000},"source":"Crossref","is-referenced-by-count":1,"title":["Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging"],"prefix":"10.1098","volume":"381","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-9403","authenticated-orcid":false,"given":"Michael J.","family":"Eck","sequence":"first","affiliation":[{"name":"Cancer Biology, Dana-Farber Cancer Institute 1 , Boston, MA, USA"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School 2 , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Scott","sequence":"additional","affiliation":[{"name":"Cancer Biology, Dana-Farber Cancer Institute 1 , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082703092584000_RSTB20240505C1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo. Clin. Proc."},{"key":"2026082703092584000_RSTB20240505C2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C3","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"2026082703092584000_RSTB20240505C4","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"2026082703092584000_RSTB20240505C5","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"2026082703092584000_RSTB20240505C6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026082703092584000_RSTB20240505C7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Cancer"},{"key":"2026082703092584000_RSTB20240505C8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"2026082703092584000_RSTB20240505C12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"2026082703092584000_RSTB20240505C13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"2026082703092584000_RSTB20240505C14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat. Cancer"},{"key":"2026082703092584000_RSTB20240505C15","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1021\/acs.jmedchem.2c00893","article-title":"Discovery of novel allosteric EGFR L858R inhibitors for the treatment of non-small-cell lung cancer as a single agent or in combination with osimertinib","volume":"65","author":"Obst-Sander","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C16","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/s41467-022-30258-y","article-title":"Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors","volume":"13","author":"Beyett","year":"2022","journal-title":"Nat. Commun."},{"key":"2026082703092584000_RSTB20240505C17","doi-asserted-by":"crossref","first-page":"117178","DOI":"10.1016\/j.ejmech.2024.117178","article-title":"From challenges to solutions: a review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer","volume":"284","author":"Ahmad","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C18","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"2026082703092584000_RSTB20240505C19","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1021\/jm400822z","article-title":"Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)","volume":"56","author":"Ward","year":"2013","journal-title":"J.Med. Chem."},{"key":"2026082703092584000_RSTB20240505C20","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"2026082703092584000_RSTB20240505C22","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092584000_RSTB20240505C23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"2026082703092584000_RSTB20240505C24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.21496","article-title":"Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers","volume":"118","author":"Shigematsu","year":"2006","journal-title":"Int. J. Cancer"},{"key":"2026082703092584000_RSTB20240505C25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"2026082703092584000_RSTB20240505C26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"2026082703092584000_RSTB20240505C27","first-page":"100459","article-title":"Osimertinib in NSCLC with atypical EGFR-activating mutations: a retrospective multicenter study","volume":"4","author":"Ji","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"2026082703092584000_RSTB20240505C28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"2026082703092584000_RSTB20240505C29","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41467-022-34398-z","article-title":"Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations","volume":"13","author":"van Alderwerelt van Rosenburgh","year":"2022","journal-title":"Nat. Commun."},{"key":"2026082703092584000_RSTB20240505C30","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1371\/journal.pmed.0020313","article-title":"Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants","volume":"2","author":"Greulich","year":"2005","journal-title":"PLoS Med."},{"key":"2026082703092584000_RSTB20240505C31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","article-title":"Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations","volume":"97","author":"Mukohara","year":"2005","journal-title":"J. Natl Cancer Inst."},{"key":"2026082703092584000_RSTB20240505C32","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1158\/0008-5472.CAN-06-0453","article-title":"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib","volume":"66","author":"Carey","year":"2006","journal-title":"Cancer Res."},{"key":"2026082703092584000_RSTB20240505C33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"2026082703092584000_RSTB20240505C34","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.21037\/jtd-24-682","article-title":"Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer","volume":"16","author":"Li","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"2026082703092584000_RSTB20240505C35","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"2026082703092584000_RSTB20240505C36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C37","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092584000_RSTB20240505C38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbapap.2009.12.010","article-title":"Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer","volume":"1804","author":"Eck","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"2026082703092584000_RSTB20240505C39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"2026082703092584000_RSTB20240505C40","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092584000_RSTB20240505C41","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"2026082703092584000_RSTB20240505C42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.critrevonc.2011.11.010","article-title":"Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence","volume":"83","author":"Ou","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2026082703092584000_RSTB20240505C43","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"2026082703092584000_RSTB20240505C44","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","article-title":"Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor","volume":"7","author":"Gonzales","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"2026082703092584000_RSTB20240505C45","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"2026082703092584000_RSTB20240505C46","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","article-title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"8","author":"Andrews Wright","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"2026082703092584000_RSTB20240505C47","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C48","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"2026082703092584000_RSTB20240505C49","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"key":"2026082703092584000_RSTB20240505C50","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026082703092584000_RSTB20240505C51","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer."},{"key":"2026082703092584000_RSTB20240505C52","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1021\/acsmedchemlett.9b00381","article-title":"Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors","volume":"10","author":"De Clercq","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"2026082703092584000_RSTB20240505C53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.bbrc.2018.05.154","article-title":"Crystal structure of EGFR T790M\/C797S\/V948R in complex with EAI045","volume":"502","author":"Zhao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026082703092584000_RSTB20240505C54","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1158\/0008-5472.CAN-13-1145","article-title":"Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization","volume":"73","author":"Cho","year":"2013","journal-title":"Cancer Res."},{"key":"2026082703092584000_RSTB20240505C55","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","article-title":"YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer","volume":"25","author":"Yun","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026082703092584000_RSTB20240505C56","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acsmedchemlett.2c00213","article-title":"Structural basis for inhibition of mutant EGFR with lazertinib (YH25448)","volume":"13","author":"Heppner","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"2026082703092584000_RSTB20240505C57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"2026082703092584000_RSTB20240505C58","doi-asserted-by":"crossref","first-page":"128718","DOI":"10.1016\/j.bmcl.2022.128718","article-title":"Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC","volume":"68","author":"Gero","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082703092584000_RSTB20240505C59","doi-asserted-by":"crossref","first-page":"PR004","DOI":"10.1158\/1538-8514.CANCERCHEM24-PR004","article-title":"Abstract PR004: brain penetrant allosteric EGFR inhibitors for NSCLC","volume":"23","author":"Scott","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"LB_C14","key":"2026082703092584000_RSTB20240505C60","article-title":"Abstract LB_C14: EAI-432: a mutant-selective allosteric EGFR inhibitor for L858R-mutant non-small cell lung cancer","volume":"22","author":"Eck","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"2026082703092584000_RSTB20240505C61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/bkcs.11491","article-title":"Allosteric inhibitor TREA-0236 containing non-hydrolysable quinazoline-4-one for EGFR T790M\/C797S mutants inhibition","volume":"39","author":"Lee","year":"2018","journal-title":"Bull. Korean Chem. Soc."},{"key":"2026082703092584000_RSTB20240505C62","unstructured":"Lee\n              KD\n            , ChoiG, LeeS, KimJ, ChoBC, ParkCW, YunJ. 2020Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer. World Intellectual Property Organization Patent No. WO\/2020\/036386A1."},{"key":"2026082703092584000_RSTB20240505C63","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11095-022-03234-w","article-title":"Chemical, analytical and pharmacokinetic characterisation of RO7304898, an API consisting of two rapidly interconverting diastereoisomers","volume":"39","author":"Heinig","year":"2022","journal-title":"Pharm. Res."},{"key":"2026082703092584000_RSTB20240505C64","unstructured":"Lee\n              KD\n            , KimJ, ChoBC, ChoiG, YunJ, ParkCW, DuggiralaKB, ChaeCH, LeeSY, GoRA. 2021Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer. World Intellectual Property Organization Patent No.WO\/2021\/101268A1."},{"key":"2026082703092584000_RSTB20240505C65","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1538-7445.AM2024-1967","article-title":"Abstract 1967: IN-119873, the next-generation allosteric EGFR TKI, a potent and highly selective EGFR L858R for the treatment of osimertinib-resistant NSCLC","volume":"84","author":"Choi","year":"2024","journal-title":"Cancer Res."},{"key":"2026082703092584000_RSTB20240505C66","unstructured":"Yu\n              M\n            , LuY, LiFGuLWangT.\n          2024\n          N-(1H-indol-2-yl)methyl)-4-ethynyl-picolinamide derivatives as EGFR inhibitors for the treatment of cancer. World Intellectual Property Organization Patent No.WO\/2024\/240241."},{"key":"2026082703092584000_RSTB20240505C67","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C68","doi-asserted-by":"crossref","first-page":"118146","DOI":"10.1016\/j.bmc.2025.118146","article-title":"A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"123","author":"Gawli","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C69","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1021\/acs.jmedchem.9b01169","article-title":"Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors","volume":"62","author":"Engelhardt","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C70","doi-asserted-by":"crossref","first-page":"e202300343","DOI":"10.1002\/cmdc.202300343","article-title":"Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase","volume":"19","author":"Beyett","year":"2024","journal-title":"Chem. Med. Chem."},{"issue":"46","key":"2026082703092584000_RSTB20240505C71","article-title":"A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer","volume":"8","author":"Suzuki","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"2026082703092584000_RSTB20240505C72","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/jacs.6b08536","article-title":"Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes","volume":"139","author":"Zhao","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"2026082703092584000_RSTB20240505C73","doi-asserted-by":"crossref","first-page":"113786","DOI":"10.1016\/j.ejmech.2021.113786","article-title":"A sulfonyl fluoride derivative inhibits EGFR(L858R\/T790M\/C797S) by covalent modification of the catalytic lysine","volume":"225","author":"Ferlenghi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C74","doi-asserted-by":"crossref","first-page":"115671","DOI":"10.1016\/j.ejmech.2023.115671","article-title":"Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry","volume":"259","author":"Tang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C75","doi-asserted-by":"crossref","first-page":"117140","DOI":"10.1016\/j.ejmech.2024.117140","article-title":"Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance","volume":"283","author":"Patil","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C76","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1039\/D3MD00439B","article-title":"A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase","volume":"14","author":"Kuki","year":"2023","journal-title":"RSC Med. Chem."},{"key":"2026082703092584000_RSTB20240505C77","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acscentsci.3c01245","article-title":"Molecular bidents with two electrophilic warheads as a new pharmacological modality","volume":"10","author":"Li","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"2026082703092584000_RSTB20240505C78","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1021\/acsmedchemlett.8b00564","article-title":"Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFR(L858R\/T790M\/C797S)","volume":"10","author":"Li","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"2026082703092584000_RSTB20240505C79","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1021\/acs.jmedchem.1c00848","article-title":"Design of a \u201ctwo-in-one\u201d mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites","volume":"65","author":"Wittlinger","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s42004-024-01108-3","article-title":"Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors","volume":"7","author":"Wittlinger","year":"2024","journal-title":"Commun. Chem."},{"key":"2026082703092584000_RSTB20240505C81","doi-asserted-by":"crossref","first-page":"21438","DOI":"10.1021\/acs.jmedchem.4c02311","article-title":"Tilting the scales toward EGFR mutant selectivity: expanding the scope of bivalent \u201ctype V\u201d kinase inhibitors","volume":"67","author":"Wittlinger","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C82","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026082703092584000_RSTB20240505C83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"2026082703092584000_RSTB20240505C84","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Edn Engl."},{"key":"2026082703092584000_RSTB20240505C85","unstructured":"Nasveschuk\n              CGS\n            \n          \u00a0et\u00a0al.\u00a02021Isoindolinone and indazole compounds for the degradation of EGFR. World Intellectual Property Organization Patent No.WO\/2021\/127561."},{"key":"2026082703092584000_RSTB20240505C86","doi-asserted-by":"crossref","first-page":"127167","DOI":"10.1016\/j.bmcl.2020.127167","article-title":"Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082703092584000_RSTB20240505C87","doi-asserted-by":"crossref","first-page":"114533","DOI":"10.1016\/j.ejmech.2022.114533","article-title":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","volume":"239","author":"Hong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026082703092584000_RSTB20240505C88","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"2026082703092584000_RSTB20240505C89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","volume":"638","author":"Zhang","year":"2025","journal-title":"Nature"},{"key":"2026082703092584000_RSTB20240505C90","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"2026082703092584000_RSTB20240505C91","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026082703092584000_RSTB20240505C92","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2026082703092584000_RSTB20240505C93","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.lanepe.2023.100592","article-title":"Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study","volume":"27","author":"Gijtenbeek","year":"2023","journal-title":"Lancet. Reg. Health Eur."},{"key":"2026082703092584000_RSTB20240505C94","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","article-title":"A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN study (LOGIK1603\/WJOG9116L)","volume":"16","author":"Yamaguchi","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"2026082703092584000_RSTB20240505C95","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tips.2020.02.001","article-title":"Combining allosteric and orthosteric drugs to overcome drug resistance","volume":"41","author":"Ni","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"2026082703092584000_RSTB20240505C96","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"2026082703092584000_RSTB20240505C97","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-025-02592-9","article-title":"Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results","volume":"39","author":"Cortes","year":"2025","journal-title":"Leukemia"},{"key":"2026082703092584000_RSTB20240505C98","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Philosophical Transactions of the Royal Society B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0505\/6162302\/rstb.2024.0505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0505\/6162302\/rstb.2024.0505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:09:43Z","timestamp":1787814583000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/381\/1957\/20240505\/483098\/Towards-better-outcomes-for-epidermal-growth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":98,"journal-issue":{"issue":"1957","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,8,20]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2024.0505","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"20240505"}}